Literature DB >> 25173530

Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.

Marcin Nicoś1, Tomasz Powrózek, Paweł Krawczyk, Bożena Jarosz, Beata Pająk, Marek Sawicki, Krzysztof Kucharczyk, Tomasz Trojanowski, Janusz Milanowski.   

Abstract

Discoidin death receptor 2 (DDR2) receptor belongs to a DDR family that shows a tyrosine kinase activity. The somatic mutations in DDR2 gene, reported in non-small cell lung cancer (NSCLC), are involved in up-regulation of cells' migration, proliferation and survival. A S768R substitution in DDR2 gene was commonly reported in squamous cell lung carcinoma. Clinical data of patients carrying the DDR2 gene mutation suggest that its presence can be independent of gender and age. The effectiveness of an oral dual-specific (Src and Abl) multikinase inhibitors-dasatinib-was observed in different cell lines and in some NSCLC patients with identified DDR2 mutation. In the present study, we have used three molecular methods (ASP-real-time PCR, ASP-DNA-FLA PCR and direct sequencing) to detect the DDR2 gene mutation in 143 patients with NSCLC metastases to the central nervous system (CNS). The prevalence of the DDR2 gene mutation was correlated with the occurrence of mutations in the EGFR, KRAS, HER2 and BRAF genes. We identified three patients (2.1% of studied group) with DDR2 mutation. The mutation was observed in two patients with low differentiated squamous cell lung cancer and in one patient with adeno-squamous cell carcinoma (ADSCC). In ADSCC patients, DDR2 mutation coexisted with G12C substitution in KRAS gene. According to the current knowledge, examination of the presence of the DDR2 gene mutation in metastatic lesion is the first such report worldwide. The information, that these driver mutations are present in CNS metastases of NSCLC, could broaden therapeutic choices in such group of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173530      PMCID: PMC4180903          DOI: 10.1007/s12032-014-0176-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

1.  Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Authors:  Hee Joung Kim; Kye Young Lee; Young-Chul Kim; Kyu-Sik Kim; Sung Yong Lee; Tae Won Jang; Min Ki Lee; Kyeong-Cheol Shin; Gwan Ho Lee; Jae Chol Lee; Jeong Eun Lee; Sun Young Kim
Journal:  Lung Cancer       Date:  2011-09-17       Impact factor: 5.705

Review 2.  New targetable oncogenes in non-small-cell lung cancer.

Authors:  Geoffrey R Oxnard; Adam Binder; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

3.  A useful protocol for analyses of mutations of the epidermal growth factor receptor gene.

Authors:  Dage Liu; Jun Nakano; Masaki Ueno; Daiki Masuya; Takashi Nakashima; Hiroyasu Yokomise; Kouichi Yube; Cheng-Long Huang
Journal:  Oncol Rep       Date:  2006-06       Impact factor: 3.906

4.  Somatic mutations of the protein kinase gene family in human lung cancer.

Authors:  Helen Davies; Chris Hunter; Raffaella Smith; Philip Stephens; Chris Greenman; Graham Bignell; Jon Teague; Adam Butler; Sarah Edkins; Claire Stevens; Adrian Parker; Sarah O'Meara; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Jody Clements; Jennifer Cole; Ed Dicks; Ken Edwards; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; Rebecca Shepherd; Alexandra Small; Helen Solomon; Yvonne Stephens; Calli Tofts; Jennifer Varian; Anthony Webb; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Anthony Green; Maggie Knowles; Suet Y Leung; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin T Teh; Siu T Yuen; Sunil R Lakhani; Douglas F Easton; Barbara L Weber; Peter Goldstraw; Andrew G Nicholson; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Authors:  Faye M Johnson; B Nebiyou Bekele; Lei Feng; Ignacio Wistuba; Xi Ming Tang; Hai T Tran; Jeremy J Erasmus; Li-Ling Hwang; Naoko Takebe; George R Blumenschein; Scott M Lippman; David J Stewart
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

6.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

7.  Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.

Authors:  C E Ford; S K Lau; C Q Zhu; T Andersson; M S Tsao; W F Vogel
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

8.  Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

Authors:  Elizabeth Day; Beatrice Waters; Katrin Spiegel; Tanja Alnadaf; Paul W Manley; Elisabeth Buchdunger; Christoph Walker; Gabor Jarai
Journal:  Eur J Pharmacol       Date:  2008-10-11       Impact factor: 4.432

9.  Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment.

Authors:  Hyun Ju Lee; Xianhua Xu; Hyojin Kim; Yan Jin; Pingli Sun; Ji Eun Kim; Jin-Haeng Chung
Journal:  Korean J Pathol       Date:  2013-02-25

10.  EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report.

Authors:  Wojas-Krawczyk Kamila; Skroński Michał; Krawczyk Paweł; Jaguś Paulina; Kucharczyk Tomasz; Jarosz Bożena; Mlak Radosław; Szumiło Justyna; Sawicki Marek; Tomasz Trojanowski; Milanowski Janusz; Chorostowska-Wynimko Joanna
Journal:  Clin Exp Metastasis       Date:  2013-07-27       Impact factor: 5.150

View more
  4 in total

1.  Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer.

Authors:  Yi Fan; Zhe Xu; Jin Fan; Liu Huang; Ming Ye; Kun Shi; Zheng Huang; Yaqiong Liu; Langchi He; Jiezhen Huang; Yibin Wang; Qiufeng Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Justyna Szumiłło; Tomasz Trojanowski; Janusz Milanowski
Journal:  Clin Exp Med       Date:  2015-04-23       Impact factor: 3.984

3.  Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Tomasz Trojanowski; Janusz Milanowski
Journal:  Brain Tumor Pathol       Date:  2017-01-17       Impact factor: 3.298

4.  Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.

Authors:  Zahra Fathi; Seyed Ali Javad Mousavi; Raheleh Roudi; Farideh Ghazi
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.